Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses
Combination Trial Aims To Improve Mortality Rate
Executive Summary
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.
You may also be interested in...
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.
Amid Supply Concerns, EU Approves Gilead’s Remdesivir
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.